산업
Pharmaceuticals
Pharmaceuticals 산업의 모든 리포트 — 총 43건.
42/100
BioNTech SE: Cash Is the Floor, Pumitamig Is the Option
BioNTech is a German biotech spending a pandemic-built reserve of EUR 16.634 billion, held at June 30, 2026, on a late-stage oncology portfolio centred on pumitamig, a PD-L1xVEGF-A bispecific whose worldwide costs and profits are split 50:50 with Bristol Myers Squibb. The August guidance cut took 2026 revenue to EUR 1.6-1.9 billion and the shares rose anyway, because at USD 96.73 financial assets of USD 19.28 billion leave only about USD 5.02 billion of enterprise value for the entire pipeline. Rating Hold: CEO succession is settled and the cash floor is real, but the price sits above the USD 91 conservative rNPV, and Akeso's ivonescimab still holds the better randomised evidence.
31/100
Relay Therapeutics: USD 3.22bn of Pipeline Value Above Cash Rests on a Phase 3 Run Against Approved Capivasertib Rather Than Placebo
Relay Therapeutics is a clinical-stage precision-oncology developer with no approved product, whose value is concentrated in zovegalisib, a mutant-selective PI3Kα inhibitor now in Phase 3. At 18.87 USD the 4.14 billion USD market capitalisation leaves about 3.22 billion USD of pipeline value above 910.9 million USD of June cash, and ReDiscover-2 has to beat AstraZeneca's approved capivasertib plus fulvestrant rather than a placebo, while the first-line case still rests on 15 responses among 34 heavily pre-treated patients. Rating Watch: the price already discounts a crowded-market success, and more than 40 million shares issued in 2026 make dilution structural rather than incidental.
53/100
94Buffett
Hansoh Pharmaceutical: One Molecule, One Royalty Book, and a Price That Already Pays for Both
Hansoh Pharmaceutical is a China-focused innovative drugmaker whose derived innovative-product sales reached RMB10.24bn in FY2025 while the legacy generic tail shrank to RMB2.68bn, sitting on RMB31.55bn of cash and a licensing platform that GSK, Merck, Regeneron and Roche have each paid real upfront cash to access. Rating Hold: at HK$33.34 the stock trades 23% above the HK$27.0 conservative sum-of-the-parts value and only about 9% below the HK$36.4 base case, so the pipeline option value is already prepaid and there is no margin of safety.
38/100
88Buffett
Pientzehuang: High-Priced Core Volume Fell 21% in 2025, and CNY132.59 Still Prices In 42x Trailing Earnings
Zhangzhou Pientzehuang is a state-controlled Chinese pharmaceutical group whose economics are dominated by the legally protected Pien Tze Huang liver-medicine franchise, alongside low-margin drug distribution and a smaller cosmetics business. 2025 revenue fell 16.56% to CNY9.001bn and attributable net profit fell 27.49% to CNY2.159bn, reported as the first simultaneous decline since the 2003 listing, and the SSE inquiry response disclosed that sales volume of higher-priced liver products fell 21% while cheaper products rose 41%. Rating Hold: the legal moat and a 62.18% Q1 franchise gross margin are intact, but at CNY132.59 the stock trades near 42x trailing earnings against a conservative value of CNY100–115, leaving no margin of safety.
37/100
Pfizer Inc.: A 6.6% Yield Costing 108% of Free Cash Flow, $17-18 Billion of Revenue Facing the Late-Decade Cliff, and No Margin of Safety at $26.20
Pfizer is a global biopharmaceutical group funding oncology, vaccines and specialty medicines from a large portfolio of patented products. Two consecutive 2026 beats and an August guidance raise show the commercial engine working, but roughly 17-18 billion of Pfizer-recognised annual revenue faces loss of exclusivity across the second half of the decade, and the 1.72 dividend already absorbs 108% of conventional free cash flow. Rating Hold: a 6.6% yield at 9.0 times guided adjusted earnings pays holders to wait, yet at 26.20 the shares sit inside the 25-32 fair range with no margin of safety.
46/100
71Buffett
Merck & Co.: KEYTRUDA and QLEX Generated 50.4% of Second-Quarter Revenue While Subcutaneous Sales Rose to 463 Million Dollars Before the 2028 Patent Cliff
Merck & Co., known as MSD outside the United States and Canada, is a global innovative-pharmaceutical company whose earnings are dominated by the KEYTRUDA oncology franchise, supported by vaccines, specialty medicines and animal health. KEYTRUDA and its subcutaneous companion QLEX produced $8.366 billion of the $16.607 billion of second-quarter 2026 revenue, or 50.4%, and that concentration must be replaced before U.S. exclusivity begins eroding after 2028, with about $16 billion already spent on Cidara and Terns for assets that still carry substantial clinical risk. Rating Hold: at the August 4 close of $128 the shares sit close to the $130 base value and 16% above the $110 conservative value, leaving little margin of safety.
49/100
Zymeworks: The Molecule Is Proven, the Allocator Is Not
Zymeworks is a biotech licensor rebuilding itself into a cash-flow aggregator: zanidatamab royalties and milestones collected through Jazz and BeOne, plus a pending Theravance acquisition that would add YUPELRI profit-share economics. The engine is real but still thin, and both of its best streams are already pledged: 30% of Ziihera royalties back a $250 million Royalty Pharma note, and 75% of YUPELRI profit share would service a $350 million OMERS note. Rating Hold: at $22.61 the shares sit inside the acceptable-hold band but above the conservative case, so investors are paying for the transition before the deal and the August 25, 2026 PDUFA resolve.
53/100
Innovent Biologics: The China Platform Is Real, but the Price Already Pre-Pays the Obesity Curve
Innovent Biologics is a China biopharma with 18 approved products, an oncology commercial base that produced RMB11.93 billion of 2025 product revenue, and a new obesity franchise built on mazdutide. 2025 brought the first full-year profit of RMB813.6 million, but headline operating cash flow of RMB10.0 billion was flattered by a RMB7.64 billion contract-liability inflow tied to Takeda's upfront. Rating Hold: at HK$89.35 and roughly 10 times trailing sales, the price already pre-pays much of the obesity and licensing upside before the economics are proven.
40/100
Shanghai Junshi Biosciences: A Real PD-1 Franchise, But the A-Shares Already Price an Unproven Profit Bridge
Shanghai Junshi Biosciences (688180.SHG) is a Chinese biopharma whose PD-1 antibody toripalimab now drives about 83% of group revenue, with 2025 revenue up 28.2% and Q1 2026 operating cash flow turning positive for the first time. The stock trades at roughly a 125% premium over its Hong Kong-listed H-shares (1877.HK) because Shanghai investors are pricing a bridge to durable, non-recurring-free profitability that management has not yet finished building. Rating Hold: commercial execution is improving fast, but the current A-share price already discounts much of that bridge, leaving little margin of safety.
47/100
Sichuan Baili Tianheng: A De-Risked ADC Story the Market Has Already Priced In
Sichuan Baili Tianheng (STAR Market 688506, English IR name Sichuan Biokin) is a China-listed oncology biotech whose legacy generics business in anesthesia, parenteral nutrition and traditional Chinese medicine still funds operations, but whose roughly CNY 141 billion market value is now dominated by iza-bren (BL-B01D1), a first-in-class bispecific EGFR×HER3 ADC licensed to Bristol Myers Squibb for $800 million upfront plus billions more in potential milestones. The core tension: 2024 revenue and profit spiked on that upfront payment (revenue up 936% to CNY 5.82 billion), then reverted to a CNY 1.05 billion net loss in 2025 as licensing income normalized, and Q1 2026 still burned CNY 741.8 million of operating cash against just CNY 94.6 million of revenue, all while iza-bren was winning FDA Breakthrough Therapy Designation and its first two China approvals in 2026. Rating Hold: a genuinely de-risked, first-in-class ADC franchise, but at CNY 329.69 the shares already sit near the middle of a reasonable fair-value band with no obvious margin of safety.
45/100
Daiichi Sankyo: A World-Class ADC Franchise, Priced as If the Supply Crisis Is Already Resolved
Daiichi Sankyo is a Japan-based, oncology-focused pharmaceutical company whose profit engine has shifted to the DXd antibody-drug-conjugate platform, led by Enhertu (partnered with AstraZeneca) and Datroway, with the Oncology unit generating JPY 608.8 billion of FY2025 revenue, up 31.3% year on year. In May 2026 the company booked JPY 214.4 billion of manufacturing-related provisions after admitting its ADC supply contracts were sized for maximum-demand scenarios, yet still posted record FY2025 revenue of JPY 2,123.0 billion and guided FY2026 core operating profit up 27.5%, even as it acknowledged that some medium- to long-term supply-cost gaps remain unrecognized. Rating Hold: world-class ADC science, but a stock that has already re-priced into the acceptable-hold zone rather than a clear bargain, with the next proof point resting on two to three clean quarters without another supply-related charge.
36/100
BioNTech SE: Cash-Rich Transition, Unproven Oncology Payoff
BioNTech is a German biotech converting one extraordinary COVID-vaccine windfall into a late-stage oncology franchise, backed by €16.8 billion of cash as of Q1 2026. Revenue is collapsing toward a seasonal COVID trough while R&D spending stays heavy, and pumitamig plus gotistobart carry most of the market's oncology hopes. Rating Hold: the balance sheet rules out a bearish call, but unresolved oncology execution and founder-succession risk keep the price fair rather than cheap.
47/100
64Buffett
Exelixis: A Real Cabozantinib Cash Machine Pricing In an Unproven Second Act
Exelixis is a commercial-stage oncology biotech whose economics still flow almost entirely through cabozantinib, sold as CABOMETYX in the U.S. and monetized abroad through royalty deals with Ipsen and Takeda. 2025 total revenue reached $2.320 billion with $782.6 million of net income and $884.3 million of operating cash flow, and the market now waits on a December 3, 2026 FDA decision for zanzalintinib in colorectal cancer, the company's attempt to build a second franchise. Rating Hold: the cabozantinib business is real and cash-generative, but at $55.75 the price already assumes a credible handoff to zanzalintinib, leaving limited margin of safety either way.
46/100
Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act
Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.
50/100
BeOne Medicines: A Real Oncology Winner, Already Priced For More
BeOne Medicines, formerly BeiGene, is a global oncology biopharma whose economics now turn on one drug, BRUKINSA, the BTK inhibitor that outsold AstraZeneca's Calquence and AbbVie's Imbruvica in 2025 with $3.93 billion of revenue as the company crossed into sustained GAAP profitability. Full-year 2025 revenue reached $5.34 billion with $1.13 billion of operating cash flow, and first-quarter 2026 extended the trend with an 89% gross margin and raised full-year guidance, even as BRUKINSA still supplies roughly three-quarters of product revenue. Rating Hold: commercial execution and BTK leadership are real and durable, but at $303.96 the stock already prices continued BRUKINSA strength and a successful platform broadening that remains unproven, leaving no meaningful margin of safety.
43/100
Legend Biotech: CARVYKTI Is a Real Franchise, Self-Funding Is Still Unproven
Legend Biotech is a commercial-stage cell-therapy company whose economics are dominated by CARVYKTI, the BCMA CAR-T it shares equally with Johnson & Johnson outside Greater China while bearing and retaining 70% in Greater China. Collaboration revenue reached 944.8 million USD in 2025 and quarterly CARVYKTI trade sales hit 597 million USD in Q1 2026, up 62% year over year, yet the same quarter still showed a 54.3 million USD net loss and June 2026 brought a follow-on offering of about 226 million USD gross. Rating Hold: CARVYKTI is a real franchise, but the current price does not pay generously for single-asset concentration, shared economics, and continuing dilution risk, and new capital only gets attractive at 22 to 24 USD.
50/100
71Buffett
UCB SA: A Specialty-Biopharma Growth Platform That Has Already Re-Rated
UCB is a Belgian specialty biopharma in immunology and neurology, and BIMZELX is now its largest product at €2.227 billion of 2025 net sales. FY2025 revenue rose 26% to €7.741 billion, adjusted EBITDA jumped to €2.636 billion, and the balance sheet swung from €1.454 billion of net debt to roughly net cash; yet at €258.50, about 24x forward earnings, the price already embeds much of the BIMZELX and portfolio ramp. Rating Hold: a genuinely stronger company at a price that leaves essentially no margin of safety for fresh capital.
42/100
Sanofi SA: A Pure-Play in Transition, Still Proving Life After Dupixent
Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.
52/100
84Buffett
GSK plc: Rebuilt Biopharma, Racing the Patent Cliff
GSK plc is a UK biopharma rebuilt around vaccines and specialty medicines after the 2022 Haleon demerger, with 2025 sales of £32.7bn anchored by Shingrix and the ViiV HIV franchise. Specialty medicines now drive growth (£13.5bn, +14% CER in Q1 2026) and core operating profit rose 11% to £9.8bn, yet the whole story hinges on replacing the dolutegravir HIV cliff in 2028–2030 before it arrives. Rating Hold: a genuinely higher-quality franchise at roughly 11.6x core earnings, but the price already assumes much of the patent-cliff bridge, leaving little margin of safety.
51/100
83Buffett
Hengrui Pharmaceuticals: A Fortress Innovation Platform, But RMB 50 Already Pays for the Upgrade
Hengrui Pharmaceuticals is China's largest listed innovative-drug platform, still earning mainly from domestic drug sales while its valuation increasingly rests on converting self-funded R&D into commercial franchises and recurring overseas licensing income. 2025 revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion and a fortress balance sheet holding RMB 40.16 billion of cash, yet at RMB 50.04 (about 41x trailing earnings) the price sits above the conservative fair value and leaves no margin of safety. Rating Hold: a rare high-quality China pharma platform already priced for an innovation-monetization upgrade it has not yet fully earned.
45/100
RemeGen: Two Self-Developed Drug Franchises and an Export Licensing Engine, With the A-Share Already Pricing a Cleaner Future Than the Filings Justify
RemeGen is a commercializing China innovative-biopharma with two self-developed franchises — telitacicept in autoimmune disease and disitamab vedotin in ADC oncology — plus an ex-China licensing engine (Vor Bio, Santen, AbbVie) that has become part of the business model. 2025 product sales reached CNY 2.31bn (up 35.8%) and reported profit turned positive at CNY 709.7m, but operating cash flow was only CNY 52.3m (about 0.07x conversion), Q1 2026 profit after non-recurring items stayed negative, and the A-share trades at roughly a 96.5% premium to the H-share — above even the optimistic per-share value. Rating Avoid: a good company at the wrong price on the Shanghai line, where an entry needs both a lower A-share price (CNY 36-40) and proof that recurring earnings quality has caught up to the approvals.
47/100
Kelun-Biotech: A Commercializing China ADC Franchise Priced for Much of Its sac-TMT and MSD Global Success
Kelun-Biotech is a commercial-stage China ADC developer whose equity value is dominated by its sac-TMT (TROP2) franchise in Greater China plus ex-China royalty economics from MSD. In 2025 product sales inflected to RMB542.7m within RMB2.06bn total revenue and the balance sheet held RMB4.56bn cash with no borrowings, yet the company still posted a RMB382.0m net loss as nearly all equity value concentrates in one molecule. Rating Hold: a real ADC franchise is forming, but at HK$419 the stock already prices in much of the sac-TMT China plus MSD global success path and offers no margin of safety.
50/100
Akeso, Inc.: A Commercial-Stage Antibody Innovator Still Priced on Ivonescimab's Global Option Value
Akeso is a commercial-stage Chinese antibody innovator with seven marketed products and record 2025 commercial sales of RMB3.03 billion, anchored by cadonilimab and ivonescimab. Yet the stock trades as a referendum on one molecule: whether ivonescimab's strong China data (a HARMONi-6 overall-survival win, HR 0.66) can survive global regulators, while 2025 operating cash flow stayed negative at RMB947.6 million and the shares fetch about 22x trailing sales. Rating Hold: rare science and a real China franchise, but the price still pre-pays too much of ivonescimab's ex-China upside; the ideal buy zone is HK$58-64.
51/100
64Buffett
아스트라제네카: 심층 리서치
아스트라제네카는 항암과 희귀질환을 중심으로 R&D와 글로벌 상업화를 통해 수익을 창출하는 혁신신약 거대 기업이다. 2025년 매출은 587.39억 달러에 이르렀고, 성장 엔진은 항암(전년 대비 +20%)과 희귀질환(+19%) 쪽으로 옮겨가 기존 CVRM 약물의 압박을 상쇄하면서, 단일 엔진 동종 기업보다 균형 잡힌 멀티플랫폼 구조를 갖추고 있다. 평가 보유: 현재 178.75달러는 보수적 내재가치 대비 여전히 프리미엄에서 거래되어 의미 있는 안전마진이 없으며, 이행 압박 국면에 진입한 고품질 종목이다.
46/100
78Buffett
Novartis (NVS) Zen Horizon Research Report
Novartis is one of the world's top ten innovative pharmaceutical companies, headquartered in Basel, Switzerland, and has repositioned itself as a pure-play innovative medicines company after spinning off Sandoz in October 2023. Its portfolio spans cardiovascular, oncology, immunology, neuroscience, and rare diseases, supported by 2025 revenue of about $56.6 billion, a 30% operating margin, roughly $15 billion in free cash flow, and 28 consecutive years of dividend increases, while Entresto's U.S. generic entry in Q4 2025 remains the key near-term challenge. Research rating Hold: a high-quality defensive compounder with a deep moat, but the current price already reflects neutral expectations and leaves limited margin of safety.
37/100
LongBio Pharma-B Vertical and Horizontal Analysis
LongBio Pharma is a China 18A innovative-drug IPO candidate whose core anti-IgE antibody LP-003 is nearing BLA submission. As of 2026-06-03, it had not yet started trading, and the HK$96.06 offer price already reflected substantial success expectations while standing well above a conservative intrinsic value of HK$67.4. Rating Watch: a zero-revenue, zero-profit biotech with value highly concentrated in LP-003 and an ideal buy price at or below HK$54.
32/100
Viatris In-Depth Investment Research Report
A global platform of generics and mature branded drugs with steady cash flow but a thin moat and middling asset quality. At roughly $16.26 the stock sits in the lower half of fair value, leaving an insufficient margin of safety. Rating Watch: a fairly priced cash-flow business that lacks the durable advantages to compound, with an ideal entry of $11-13.5.
44/100
Moderna: A Long-Term Business Owner's Perspective
Moderna is an mRNA-platform biopharmaceutical company that began with COVID vaccines and still has adequate cash, but has entered a cash-burning transition period that depends on new products taking over. Its value depends heavily on a small number of approvals and Phase 3 oncology outcomes, while the margin of safety is insufficient. Report rating Watch: a technically strong but highly uncertain platform asset that should stay on the watchlist rather than in a conservative core portfolio.
47/100
56Buffett
Incyte Zen Horizon Analysis Report
Incyte is a commercial-stage biopharma company with strong cash flow but an unproven post-Jakafi transition. The core debate is whether Opzelura, Niktimvo, Monjuvi/Minjuvi, Zynyz, and the late-stage pipeline can offset real 2028 patent pressure while preserving earnings power. Report rating Watch: at $97, the stock lacks enough margin of safety relative to a fair buy range of $80-88.
47/100
84Buffett
Zoetis Long-Term Business Owner Value Analysis
Zoetis is the global leader in animal health, with roughly 300 product lines, 2025 revenue of $9.467 billion, gross margin of 71.8%, ROIC of about 29%, and FCF of $2.283 billion. The core thesis is a high-quality, cash-generative animal health compounder whose valuation has fallen to a reasonable-to-low range, although the -11% decline in U.S. companion animal revenue in Q1 2026 is a real crack to monitor. Research rating Cautious Buy: a durable business near fair value, suitable for disciplined staged entry rather than an aggressive full position.
48/100
82Buffett
Johnson & Johnson Deep Value Analysis: A Good Company Is Not Cheap
JNJ is an understandable healthcare leader with a deep moat and stable free cash flow. The core view is that the stock price of $234 is already close to the upper end of the model's optimistic case, while its 3.4% cash return is below the 10-year Treasury yield of 4.57%, so new buyers should wait. Research rating Watch: a high-quality compounder, but the margin of safety is not sufficient at the current price.
55/100
58Buffett
Eli Lilly Deep Value Research: A Great Company at Too High a Price
The tirzepatide platform has put Lilly at the top of the metabolic disease arena, but the $732 share price has already paid in advance for the next-generation pipeline and capacity expansion; a neutral DCF intrinsic value of only $560-680 leaves an insufficient margin of safety, making it better to wait for a pullback. Rating Watch: a great business whose current price gives long-term owners too little room for error.
46/100
71Buffett
Merck Research from a Long-Term Business Owner's Perspective
Merck is a global innovative pharma leader, with Keytruda accounting for 49% of 2025 revenue. At the current price of $122.41, its FCF yield is only 4.1%, below the 10-year U.S. Treasury yield and offering insufficient margin of safety against the 2028-2029 patent cliff. Research rating Watch: a high-quality business, but the price does not yet compensate enough for the post-Keytruda transition risk.
40/100
Pfizer: A Long-Term Business-Owner's Investment Research
Pfizer is a large-cap pharmaceutical company in a recovery phase: 2025 revenue of $62.58 billion and operating cash flow of $11.70 billion, with the core ex-COVID business up 6% and dividend coverage comfortable. The Vyndaqel patent settlement extends exclusivity to 2031, but the Seagen and Metsera capital-allocation bets have yet to prove out. Rating Watch: at $25.85, the stock sits near neutral intrinsic value, with a fair buy range of $18-21.
43/100
27Buffett
Bristol-Myers Squibb: A Deep Value-Investing Study
A global large-cap pharma leader earning from patented, branded, and biologic drugs plus collaboration profit-sharing, with 2025 revenue of $48.19 billion, FCF of $12.85 billion, and a 4.24% dividend yield. At $59.46 the shares screen like a value stock and the ideal buy range is $45–52, but a patent cliff compounded by uncertain pipeline succession leaves the margin of safety too thin. Rating Watch: cheap for a reason, worth tracking rather than buying aggressively.
49/100
59Buffett
Vertex Pharmaceuticals: A Long-Term Owner's View
Vertex is a high-quality biopharma company anchored by a deep CF franchise, 86.2% gross margin, and $13 billion of net cash. The core issue is concentration: 98.5% of product revenue still came from CF, diversification beyond CF remains early, and the current valuation already prices in meaningful pipeline success. Research rating Watch: a durable compounder worth following closely, but the current price does not offer enough margin of safety for a balanced, conservative investor.
48/100
83Buffett
Regeneron Pharmaceuticals Value Analysis from a Long-Term Business Owner's Perspective
Regeneron is an integrated innovative biologics leader anchored by Dupixent profit sharing and the handoff to EYLEA HD and Libtayo. The company generated $4.5 billion in 2025 net income and holds $15.8 billion in net cash, while the current price of $642.59 and 15.7x P/E sit in a holdable range with a thin margin of safety and an ideal buy zone of $450 to $550. Rating Watch: a high-quality compounder, but EYLEA erosion and pipeline uncertainty require patience on price.
45/100
Insmed: A Deep-Dive Value Investing Research Report
A high-quality but high-expectation respiratory-specialty biotech. ARIKAYCE and BRINSUPRI are scarce respiratory assets, but at roughly $109.5 the stock already prices in multiple successes, owner earnings remain negative, and the margin of safety is thin. Rating Watch: a good company at an ungenerous price, with a fair buy range of $55–70.
47/100
67Buffett
Gilead Sciences In-Depth Value Investment Research
Gilead is a mature biopharma company with a real HIV moat and solid cash generation, with 2025 revenue of $29.443 billion and free cash flow of about $9.456 billion. At the current share price of about $130.50, investors are already paying in advance for acquisitions and the next pipeline handoff, leaving no obvious margin of safety. Research rating Watch: conservative intrinsic value is $70-90, fair value is $100-125, and the optimistic case is $145-165 per share.
45/100
73Buffett
AbbVie: In-Depth Research from a Long-Term Business Owner's Perspective
AbbVie has cleared the Humira patent cliff, with Skyrizi/Rinvoq taking over as twin engines (together about 42% of 2025 revenue), backed by strong cash flow and a solid dividend; at the current $212.30 the margin of safety is thin and book equity is negative, so the rating is Watch, with an ideal buy range of $155-180.
47/100
Alnylam Pharmaceuticals Deep Value Investment Analysis
Alnylam is an RNAi innovator that reached its first full-year profit in 2025, with AMVUTTRA driving rapid commercialization. The core thesis is that the business has moved beyond a platform story, but revenue concentration, SBC, and financing complexity leave limited margin of safety at about $299. Research rating Watch: a durable company may be emerging, but an ideal entry point is closer to $200-240.
43/100
67Buffett
Amgen Inc. Deep-Dive Value Investing Analysis
A high-quality but currently not-cheap mature biopharma asset; under a patent cliff, Medicare price cuts and a heavier balance sheet after the Horizon acquisition, the ~$331 price lacks a margin of safety, with an ideal buy range of $240-280. Rating: Watch.
52/100
88Buffett
Novo Nordisk: A Long-Term Owner's Perspective
A high-quality pharma business: ROIC sits at a lofty 39-88%, with 55% share in once-weekly injectable GLP-1. But facing Lilly's oral GLP-1 launch, U.S. pricing policy, and semaglutide losing exclusivity in some international markets, the stock trades at 20-23x on an Owner Earnings basis. Rating Watch: the cheapness of a static 12.5x PE is an illusion, and today's price offers no clear margin of safety.